There are now 8 drugs developed by companies funded by the Dementia Discovery Fund in clinical trials.

There are now more than 230 trials assessing potential new treatments for dementia taking place across the globe.

Teams from our Drug Discovery Alliance are currently investigating more than 20 potential new treatments for dementia.

There are now more than 165,000 active dementia researchers worldwide and over 11,000 in the UK.*

We've now invested more than £188m in over 1,100 projects.

Dementia researchers working globally

Studies we've funded or co-funded have led to the publication of over 3,300 research papers, sharing vital discoveries with the global research community.

Discoveries funded and co-funded by ARUK

Global dementia research

Our researchers have collaborated with institutions in 74 different countries.

Our researchers have worked with institutions in 74 different countries.

Our research spend

We've now funded more than 500 researchers from over 100 different organisations.

We've now funded more than 500 researchers from over 100 different organisations.

Our research impact

Global dementia research

Dementia researchers working globally

Dementia research is more collaborative than ever. On average, there are more than 7 co-authors working together on each publication.

There are now more than 230 trials assessing potential new treatments for dementia taking place across the globe.

Discoveries funded and co-funded by ARUK

Our research spend

Active researchers defined as those who have co-authored at least one paper in either the year specified or previous year (e.g. active researchers in 2021 published papers in 2020 or 2021).
Alzheimer’s Research UK is the UK’s leading dementia research charity. We’re dedicated to understanding the causes of dementia and developing ways to prevent, treat and ultimately, cure, all forms of the condition.

We exist to make breakthroughs possible.

Contents
04 Introduction
05 Funding research to transform lives
07 Improving understanding
09 You’re accelerating progress
12 Being the best we can be
14 Looking to the future
15 Our finances
17 Our thanks
Over the last two years, we’ve been vocal about the risk these challenges pose to research progress – and your response has been incredible.

Thanks to you, 2021/22 was a record year for Alzheimer’s Research UK.

We invested £28.6m in our charitable activities, including £23.6m in pioneering research (up 36% on last year) and a further £5m in improving understanding of dementia and creating the best possible environment for research breakthroughs.

A staggering 63,000 people now make monthly donations to support our work, with more than 10,000 of these amazing supporters joining us in the last 12 months. More people than ever chose to leave a gift to dementia research in their Will this year. And we received even greater support from philanthropists and charitable trusts. The list goes on.

This was a year for re-establishing and strengthening connections.

We were thrilled to reconnect with supporters at events like the London Marathon, strengthen relationships with decision-makers in government at our House of Commons event marking World Alzheimer’s Month, and bring the research community together at our Dementia Research Conference in Brighton.

And building on foundations laid last year, supporting researchers in the early stages of their careers – those most affected by the pandemic – remained a priority. Working with our Research Network, we identified the major challenges and barriers to success faced by early career researchers and used these to shape a new programme of support to foster the next generation of research leaders.

I hope you enjoy reading about this and all the achievements that you made possible in the pages ahead.

Your support means that momentum towards a world free from the fear, harm and heartbreak of dementia has not been lost.
Thanks to our incredible supporters, we invested £28.6m in our charitable activities between April 2021 and March 2022, including £23.6m in pioneering research (up 36% on last year).

We’re fostering the next generation of research leaders

Talented, highly-driven researchers are the lifeblood of all scientific discoveries. But with many funding opportunities redirected to support the global response to COVID-19, the pandemic piled extra pressure on those working in dementia research.

This pressure was felt most acutely by early career researchers whose work is often reliant on short-term grant funding. So this year, we launched a new programme of support to nurture future research leaders. We have already:

• Invested over £1.2m in six new projects led by early career researchers.
• Introduced the Early Career Researcher Bridge Fund to help retain talented researchers.
• Established a mentorship scheme and career development groups.

Our researchers are sharing vital discoveries

Alzheimer’s Research UK-funded researchers published an unprecedented 538 research papers in 2021, up from 459 in 2020. These papers are an important indicator of research progress, each one revealing a new discovery and bringing our collective understanding of the diseases that cause dementia into sharper focus.

Highlights included:

• A potential new blood test to detect damage to the brain after a head injury. By measuring levels of neurofilament light, a protein that’s important in the structure of nerve cells, this breakthrough could bring about a more accurate way to predict those at higher risk of developing dementia.
• A clearer understanding of a major Alzheimer’s risk gene. This study found that although having a gene called APOE4 increases our risk, it’s also linked with better performance on ‘visual working memory’ tests. Understanding genes like APOE4 is crucial in building a clearer picture of how Alzheimer’s develops - and how we can intervene.
• Research to support a healthy blood-brain barrier. This barrier serves as a filter, stopping harmful substances from passing into the brain, but in Alzheimer’s disease it starts to break down. This year, researchers developed a ‘lead molecule’ (the foundation of a new drug) that could help keep it working properly.
We’re helping turn breakthroughs in the lab into life-changing new treatments

We continued to support several initiatives at the cutting edge of translational research this year, including committing a further £5m to the Dementia Discovery Fund (DDF). This venture capital fund has already invested £250m in 18 biotechnology companies in the UK and US working on new dementia treatments.

AviadoBio, established with DDF support this year, is aiming to develop a new treatment for frontotemporal dementia that acts on a person’s genes. Clinical trials of the treatment are due to start in late 2022 and if successful, it could permanently correct faulty genes and transform the lives of those affected.

We’re working at the forefront of technology

Through our Early Detection of Neurodegenerative diseases (EDoN) initiative, we’re working to revolutionise the way we detect the diseases that cause dementia and keep people connected to their worlds, their families and themselves for longer.

By combining data from wearable devices that monitor how we sleep, talk or even use our phones with clinical tests including brain scans, we will identify digital ‘fingerprints’ that indicate the earliest signs of disease.

This year, we moved into the data collection phase, with 32 research volunteers at Boston University now collecting data using the first version of our digital toolkit that combines a smartphone app, smartwatch and headband.

Heidi’s epic adventure

Heidi was determined to take action after her great uncle, Ian, was diagnosed with Alzheimer’s disease in 2020. So she embarked on an epic adventure, walking the equivalent distance between Land’s End and John O’Groats to raise money for dementia research.

The seven-year-old completed walks in her local area with family and friends, totalling up her mileage and plotting progress on a map. As she made her way up the UK, she enjoyed learning about the history, culture and people of the towns she passed through.

Having started the challenge in March 2021, Heidi reached her 603-mile target in June this year and raised more than £16,000.

“I really enjoyed this adventure. I met lots of lovely people on my walks and I’m so happy I raised so much money to help my great uncle and other people like him.”
We’re **improving understanding of dementia** and creating the best environment for research.

We’re confronting misconceptions and showcasing the value of research

Our brains are the smartest thing in the universe, responsible for all we’ve ever created. At the end of 2021, our brand film ‘The Smartest Thing’ underlined the power of the human brain to overcome deadly diseases like Alzheimer’s and the hope that lies in research. Fronted by celebrity supporter Shobna Gulati, the film reached 32 million people across 60 countries.

We responded to 3,724 enquiries to our Dementia Research Infoline this year (up 30% on 2020/21), helping guide and reassure anyone with concerns about symptoms or queries about how to get a diagnosis or take part in research.

And working with the National Institute for Health Research, Alzheimer’s Society and Alzheimer Scotland, we helped over 15,000 people play their part in research by enrolling in a study through the national Join Dementia Research service.

We’re showcasing research progress

Our online Lab Notes events, designed to make learning about research fun and accessible, proved as popular as ever this year. Over 1,000 people joined us live for events including ‘Gender, diet and brain health’ and ‘Hearts and minds: understanding vascular dementia’, with a further 10,000 views of the series on our YouTube channel.

We were delighted to reopen our unique public engagement grant scheme; the Inspire Fund, with a special focus on projects that help reach underserved audiences and communities. Eight projects received funding, including workshops to identify and address barriers to people from Black, African and Caribbean backgrounds taking part in research, and an immersive 360-degree show to help students and community groups learn about the brain and how it’s affected by dementia.
We’re championing good brain health for all

With an ageing population and no treatments currently available in the UK to stop or slow the diseases that cause dementia, we need to make more people aware of the steps they can take to look after their brain and reduce their risk of developing dementia.

In February 2022, we launched the second phase of our Think Brain Health campaign, using social media and radio adverts to encourage people to pause and consider everything their brain does for them. Our website’s brain health hub featured content including 40 brain health tips showcasing the breadth of simple steps we can take to give back to this incredible, but often under-appreciated organ.

And we brought together organisations including Alzheimer’s Society, the Royal Society for Public Health and the UK Faculty of Public Health, creating a cross-sector consensus statement on how we can work together to prioritise protecting the nation’s brain health.

We’re working with key decision-makers to tackle the challenges in dementia research

We worked hard to cement our relationships with decision-makers in government this year, mobilising our incredible volunteer campaigners to ensure dementia research is high on the political agenda.

Our House of Commons event marking World Alzheimer’s Month in September was a real highlight, helping us underline the urgent need to secure more research funding. Over 120 MPs from all parties attended with many sharing experiences of how dementia has touched their lives.

And we welcomed opportunities to shape national policy aimed at improving the research landscape. This included partnering with the Department of Health and Social Care to lead the research elements of the government’s upcoming 10-year dementia strategy.

We’re reaching more people in the media and online

We generated even greater media interest in dementia research, with our work featured in the news 8,400 times. The year’s biggest stories included:

- **US approves first Alzheimer’s drug in nearly 20 years**: In June 2021, the US Food and Drug Administration approved the first new Alzheimer’s drug in 20 years, aducanumab. Then in December, the European Medicines Agency (EMA) concluded that it was unable to licence the drug for use in Europe as the data didn’t show a clear benefit to patients’ lives.

  Our Chief Executive, Hilary Evans, provided expert commentary on both stories, explaining why the EMA’s decision must be a catalyst for increased and sustained investment.

- **Scott Mitchell runs London Marathon, raising money in memory of Dame Barbara Windsor**: In October 2021, Scott Mitchell, Alzheimer’s Research UK ambassador and husband of the late Dame Barbara Windsor, took on the London Marathon in Barbara’s memory. Scott’s marathon journey generated more than 300 pieces of coverage, helping raise over £170,000.
Our supporters donated a record £39m in 2021/22, helping keep momentum towards life-changing treatments going.

You’re powering more research than ever
We’re grateful to every single person who chooses to support our work.
An astonishing 63,000 people now make monthly donations, with more than 10,000 of these generous donors joining us in the last 12 months.
And we were humbled and inspired by those who chose to support us with a gift in their Will. We received more than £10m from 348 people who left us a legacy. A further £2m was generously donated in memory of a loved one.

We’re reconnecting with our amazing supporters
After having to postpone or cancel events during the pandemic, reconnecting with supporters in person was a real highlight for all of us at Alzheimer’s Research UK.
Sunday 3 October 2021 was a fantastic day as the London Marathon returned to the capital. More than 400 runners took to the streets in #TeamARUK orange, raising over £1m across this event and the 2020 virtual event. As ever, our supporters turned out in force, creating a carnival atmosphere to propel our runners over the finish line.
Brand new this year, we held three Facebook Challenge events, enabling supporters to fundraise, share progress, and connect with others taking on the same challenge. Of these, ‘Walk 28 miles in February’ really caught the imagination of Facebook users, with 4,192 supporters lacing up their trainers to raise over £500,000.
Our passionate partners are standing with us

We’re extremely grateful for the continued support of all our long-term Corporate Partners who include The Iceland Foods Charitable Foundation, The Perfume Shop, Ricoh, Dyson, ICAP and Lewis Silkin.

Together, our wonderful partners raised more than £2.5m this year.

New for 2021/22, our ‘Lake District House Draw’ partnership with Omaze UK gave entrants the chance of winning a million-pound dream house while helping power essential research studies. The partnership raised a transformational £1m while enabling us to reach hundreds of thousands of people up and down the UK.

And we were delighted to build on relationships with philanthropists, charitable trusts and foundations, whose steadfast support was a huge source of encouragement throughout the pandemic.

Income from major donors and trusts grew to £9.7m, including a further £1.5m in funding from Race Against Dementia, a charity founded by Sir Jackie Stewart OBE, and a £3m pledge from the Q Charitable Trust.

“The most important thing for me is hope”

Olive was diagnosed with vascular dementia in 2017. Despite her diagnosis she is determined to do everything she can to support dementia research while she is still able. Her fundraising challenges to date include completing the 780km Camino de Santiago trek through France and Spain in 2018 and walking 5km every day for a month in 2021.

Olive and her husband, Ronnie, have also chosen to rewrite their Wills to include a gift to fund life-changing dementia research.

“I know that developments in dementia research are likely to come too late for me. This condition will rob me of my life. But the most important thing for me is that there is hope that treatments will be found to slow down and stop dementia so future generations will not be affected.

“I have six grandchildren and I hope that in their lifetimes’ dementia will become something that people no longer need to worry about. But this will not happen without support for research.”
By striving for excellence in everything we do, we can put life-changing treatments in the hands of those who need them sooner.

**We’re committed**

to being the best we can be for everyone affected by dementia.

By striving for excellence in everything we do, we can put life-changing treatments in the hands of those who need them sooner.

**We’re proud to be recognised as a great place to work**

To achieve our vision of a world free from dementia, our work needs to reach, and be shaped by, people from all walks of life, no matter their background, identity or experience.

We launched our Equity, Diversity and Inclusion strategy in June 2021, helping ensure we fund research that’s representative of the population living with dementia, support a diverse research workforce and champion the equity, diversity and inclusion of our employees.

We’ve made progress on all fronts this year, including:

- Collecting data from the researchers we fund to better understand the make-up of the dementia research community.
- Co-producing resources on dementia for people with learning disabilities with Nottingham City Learning Disability and Autism Partnership Board.
- Sharing content created by employees, for employees, on topics including Pride, Mental Health Awareness Week, Black History Month, menopause and neurodiversity.
- Collecting data from employees to help us monitor progress in improving the diversity of our people.

And we used the Best Companies b-Heard survey to listen to our employees and identify opportunities to improve. We’re proud that Alzheimer’s Research UK was awarded a 2-star accreditation for the second year running, recognising ‘outstanding’ levels of employee engagement, and included in the ‘UK’s 100 best large companies to work for’.
Maximising and demonstrating our impact

Our 1,400 passionate volunteers play a crucial role in maximising our impact, whether through sharing their personal experiences of dementia, campaigning to ensure that research remains a political priority or cheering for #TeamARUK at sporting events throughout the year.

This year, we developed our Volunteer Vision and Strategy to help us attract, engage and retain a diverse group of volunteers and deliver a consistently high-quality experience that places volunteers at the heart of our charity.

More than 300 new volunteers joined us during the year, with our online Volunteer Connect events helping volunteers, new and experienced, form closer links with the charity, our employees and each other.

Finally, to maximise support for our cause, we need to accurately demonstrate the momentum gathering in dementia research. That’s why this year, we expanded our Impact Hub, a resource that helps employees communicate progress being made. The hub combines statistics on the charity’s impact (including research spend, institutions funded, and discoveries made) with data on the wider dementia research landscape.

Going for Gold

In June 2021, Olympic gold medallist Imran Sherwani made a huge contribution to helping raise awareness of dementia by bravely announcing his diagnosis of young-onset Alzheimer’s disease.

Imran, who scored two goals in the final as the Great Britain men’s hockey team won gold at the 1988 Olympics in Seoul, was diagnosed with Alzheimer’s in 2019, aged just 57.

He shared his diagnosis to support the launch of a team of runners taking on the 2021 London Marathon to raise money for dementia research in his honour.

The team, aptly named Going for Gold, was set up by fellow gold medallist Steve Barchelor and included Imran’s sons Zac and Aaron. Together, they raised over £45,000.

“I have gone from fighting the disease to accepting it, and that has made every day easier to live through. Every day of my life, I am thankful for having wonderful people around me, especially my lovely wife and my family.

“I’m so thankful to Steve and the team for raising so much money for Alzheimer’s Research UK. It’s also wonderful to know that so many people are still inspired by what we achieved in Seoul 34 years ago.”
Looking to the future Together, we will build on progress made this year.

Almost one million people in the UK are living with the dementia right now – up 25% in the last decade.

With no treatments currently available in the UK to stop the diseases, like Alzheimer’s, that cause this devastating condition, we must not underestimate the scale of the challenge that lies ahead.

But as we reflect on everything your support has made possible in 2021/22 and look ahead to the next 12 months, there are so many reasons to be optimistic.

We look forward to launching our new research strategy in late 2022. Building on the most important research breakthroughs in recent years, the strategy will have a major focus on increasing capacity for clinical trials - testing the effectiveness of potential new treatments in people.

We will maintain our efforts to support a diverse research workforce, introducing a new process, including a narrative CV format, for researchers applying for funding. Through this new approach, we aim to empower researchers to demonstrate a wider range of contributions to the field and remove barriers to making an application.

We will scale up data collection for our pioneering Early Detection of Neurodegenerative diseases initiative, and by the end of 2022, will have recruited up to 450 research volunteers. By using our digital toolkit to monitor and share data on the way they move, sleep and interact with others, these volunteers will help pinpoint subtle variations in these behaviours that could signal the presence of diseases in their very earliest stage.

We will work with government and the wider dementia community to ensure that the lessons learnt from the successful establishment of the Vaccine Taskforce, which helped accelerate the development and manufacture of a COVID-19 vaccine, are applied to dementia research.

We will continue to drive up understanding of dementia, and support for the work we do. In the year ahead, we will launch our Dementia Community Champions project - upskilling new volunteers to improve understanding of the diseases that cause dementia and opportunities to take part in research within their local community.

Finally, building awareness of the steps we can take to protect our brain health will remain a priority. The third phase of our Think Brain Health campaign will help individuals better understand their own brain healthy behaviours and the impact that the little things we do day in, day out, can have.
Our finances

With your support, we funded more groundbreaking research in 2021/2022 than ever before.

You enabled us to invest **£28.6m in our charitable activities**, including **£23.6m in pioneering research studies** and a further **£5m** in improving understanding of dementia and creating the best possible environment for research.

Our income

<table>
<thead>
<tr>
<th>Income from</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Voluntary donations</td>
<td>£39,176,936</td>
</tr>
<tr>
<td>Income from charitable activities</td>
<td>£1,610,645</td>
</tr>
<tr>
<td>Other trading and income generating activities</td>
<td>£319,196</td>
</tr>
<tr>
<td>Other income</td>
<td>£995,057</td>
</tr>
<tr>
<td>Investment income</td>
<td>£63,117</td>
</tr>
<tr>
<td>Net income in joint venture operations</td>
<td>£21,953</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>£42,186,904</strong></td>
</tr>
</tbody>
</table>

Our expenditure

<table>
<thead>
<tr>
<th>Expenditure on</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charitable activities</td>
<td>£28,611,918</td>
</tr>
<tr>
<td>Cost of generating funds</td>
<td>£12,909,525</td>
</tr>
<tr>
<td>Net expenditure in joint venture operations</td>
<td>£3,379,198</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>£44,900,641</strong></td>
</tr>
</tbody>
</table>

* Our expenditure exceeded income this year as we invested saved income from previous years in funding more research.

How do we use your donations?

For every **£1** donated to the charity

- 73p **powered our research and helped people to understand and take action on dementia.**
- 27p **helped to raise the next £1 and fund essential running costs.**
A quick guide to dementia

Our ‘Quick guide to dementia’, available in English and eight other languages, provides the basic facts about dementia in easy-to-understand terms:
alzres.uk/quick-guides

Full 2021/22 Annual Report

For a more detailed picture of our work and progress made during the last financial year, please read our Annual Report:
alzres.uk/annual-reports

Early Detection of Neurodegenerative diseases (EDoN)

With a wealth of digital data at our fingertips, now is the time to transform the early detection of the diseases that cause dementia:
edon-initiative.org

Our promise to you

We’re dependent on the generosity of you, our supporters, to fund our pioneering research programmes. Here’s what you can expect from us in return:
alzres.uk/our-promise

Think Brain Health

We want everyone to know the key ingredients to good brain health and feel empowered to act on that knowledge. Find out how taking positive steps can help reduce dementia risk:
alzres.uk/think-brain-health

How you can help

Want to play your part in overcoming dementia? There are lots of ways to get involved, from making a monthly donation to volunteering at one of our events:
alzres.uk/get-involved

Find out more about our work to bring an end to dementia.
We would like to thank everyone who chose to support us in 2021/22.
Thank you

Your donations, however big or small, are driving research that will transform the lives of people with dementia. Thank you for believing in the power of research.

These people and organisations have made an exceptional contribution to our work:

Adint Charitable Trust
Amazon Smile
Andy Ball
Aston Lark
Bally's Corporation
Benevity
Bloomberg
Caroline van den Brul, in memory of David Hague
Cheffins
Christopher Carter
Clive Watson & Mary Hayes
CMS
Daniel Jones
David and Susan Lloyd
Dr Uday Pathak
Dunelm Group
Dyson
Fort Trustees Limited
Garfield Weston Foundation
Gennets Charitable Trust
George Leventis
George Weir
Gerrards Cross Golf Club
Gibsons Games
Giveacar Ltd
Guy & Anne Morton
Harebell Centenary Fund
Heidi Barker (Aged 6)
Houghton Dunn Charitable Trust
Humble Bundle
In memory of Frankie Broadhurst
J Macdonald Menzies Charitable Trust
J.P. Morgan
Jost Foundation
Karen Penny - The Penny Rolls On
Kevin House
Kusuma Trust
Lewis Silkin LLP
Lord & Lady Fink
Loughborough Students' Rag
Majid & Lynn Jafar
Major Mick Stanley
Margaret Giffen Charitable Trust
Mark Gouldthorpe
Masonic Charitable Foundation
Mattioli Woods plc
Mercedes AMG-Petronas Formula One Team
Mishcon de Reya LLP
Mr & Mrs Colm Kelleher
Northwood Golf Club
OdysseyRe
Oliver Shanley
Patrick Davies
Peacock Charitable Trust
Peter & Madeleine Baines
Peter Dixon Charitable Trust
Peter Mills, in memory of Annie Mills
Playtech
Rahul Moodgal
Reed Smith LLP
Richard Wilkins
Robbie Horton, Hugo Rankin & Ned Holland-Hibbert
Royal Antediluvian Order of Buffaloes
Grand Primos Appeal
Schroders Personal Wealth
ShareGift
Shropshire Fundraising Group
Sir David Ord
Summer Wilson Charitable Trust
The Antares Trust
The Barbour Foundation
The Basil Samuel Charitable Trust
The Boltini Trust
The Bradley & Kathleen Wickens Foundation
The Cadogan Charity
The Carr-Gregory Trust
The Classic at Silverstone
The Constance Travis Charitable Trust
The D’Almeida Charitable Trust
The David & Christine Lloyd-Jones Foundation
The de Laszlo Foundation
The Holbeck Charitable Trust
The Laurence Misener Charitable Trust
The Lyons Charitable Trust
The Michael and Sarah Spencer Foundation
The Murdoch Forrest Charitable Trust
The Northwick Trust
The Ofenheim Charitable Trust
The Patricia Wood-Smith Scholarship Fund
The Ranworth Trust 1985
The Revere Charitable Trust
The Ross Warburton Charitable Trust
The Saintbury Trust
The Symondson Foundation
TheRunningManZ
Tim & Beatrice Guest
Tim Wise
Tolkien Trust
UK Cycling Events & Maverick Race
UK Finance
Whitbread Group plc
Woburn Golf Club
Zac Sherwani

Thank you to everyone who remembered us through a gift in their Will, including:

Alicia Brockes
Amelia Mingham
Anne Broadwater
Anne Semple
Brenda Stone
Celia Reuter
Christopher Cobley
Daphne Fisher
Daphne Pritchard
David Fielding
David Seddon
Dominic Dowell
Doreen Badcock
Doris Lennon
Eileen Dugdale
Eric Marlow
Gloria Behan
Henry Charity
Jack Taylor
Jean and Eric Baker
Jean Grey
John Banks
John Ross
Joyce Rutter
Judy and Phil Small
Kenneth Amies
Lucille Sage
Margaret Davies
Margaret Dickson Harper
Margaret Mary Bettens
Maria Hetherington
Marion Sottolini
Mary (Maura) Hills
Mary Margaret McQuaid
Maurice Smith Gates
Norman and Margaret Slack
Olive Brennan
Penelope Sullivan
Peter Coon
Rosalind Bussell
Roy and Barbara Fuller
Roy Tracey
Sidney Hadlum
Sidney Wheldon
Stephen John Brodie
Sylvia West
Ted Habbershaw
Vera Bowles
Thank you to our Pioneers’ Circle members:

David Barnett  
David Mayhew  
Denise Coates Foundation  
Financial Times  
Frank Rothwell  
Goldman Sachs  
Iceland Foods Charitable Foundation  
Lady Susan Kulukundis CBE  
Mr & Mrs Alan Howard  
Omaze UK  
parkrun UK  
Pat & Jimmy Hamilton  
Quin family via The Q Charitable Trust  
Race Against Dementia  
Ricoh Europe  
Sir KS Li - Li Ka Shing Foundation  

Stephen Catlin  
The ALBORADA Trust  
The Charis Trust  
The Joseph and Lilian Sully Foundation  
The Lyndal Tree Foundation  
The Michael Bishop Foundation  
The Mike Gooley Trailfinders Charity  
The Perfume Shop  
The Rainwater Charitable Foundation  
The Rt Hon David Cameron  
The Syncona Foundation  
Virgin Money Plc  
Wickes

Thank you to our Accelerate Club members:

Andrew Balls & Erica Wax  
Andrew Shilston  
David A Lewis & Susan J Lewis  
David Barnett  
Edward & Lesley Lambourne  
James & Deborah Crowley  
Jan Hall OBE  
Robert and Jill Le Blanc Charitable Trust  
Stephen Catlin  
The Eric and Margaret Kinder Charitable Trust  
The Fieldrose Charitable Trust  
The Jean Corsan Foundation  
Tim Oliver

Thank you to those kindly supporting EDoN:

Bill Gates  
Convex Insurance  
Iceland Foods Charitable Foundation  
The Alzheimer’s Drug Discovery Foundation Diagnostics Accelerator  
The Connolly Foundation (UK) Limited  
The Roger Quin Breakthrough Fund  
TP ICAP via ICAP Charity Day

We would like to thank all those who have donated and chosen to remain anonymous.
Alzheimer’s Research UK is the UK’s leading dementia research charity.

alzheimersresearchuk.org